Stefan Pöhlmann

2 ta ish

University of Göttingen

1. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

   Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder +10

   Maqola202010 iqtibos

   ABIABI:AkademIndex/2026.other.508188

2. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

   Markus Hoffmann, Hannah Kleine‐Weber, Nadine Krüger +3

   Preprint20202 iqtibos

   ABIABI:AkademIndex/2026.other.507180